![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1662, 2008-01, pp. : 17-17
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Solifenacin effective to the core of OAB
Inpharma, Vol. 1, Iss. 1536, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Solifenacin economically dominant in OAB
Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Solifenacin still shining in OAB
Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Solifenacin economically dominant in OAB
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 563, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Solifenacin economically dominant in OAB
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 521, 2007-01 ,pp. :